These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25965900)

  • 1. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
    Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
    Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
    Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
    Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
    Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
    Mittra ES; Goris ML; Iagaru AH; Kardan A; Burton L; Berganos R; Chang E; Liu S; Shen B; Chin FT; Chen X; Gambhir SS
    Radiology; 2011 Jul; 260(1):182-91. PubMed ID: 21502381
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Toriihara A; Duan H; Thompson HM; Park S; Hatami N; Baratto L; Fan AC; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1518-1523. PubMed ID: 30850872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
    Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
    Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
    J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data.
    Smeets P; Ham H; Ceelen W; Boterberg T; Verstraete K; Goethals I
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):327-32. PubMed ID: 20639817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.
    Chiang GC; Galla N; Ferraro R; Kovanlikaya I
    J Neuroimaging; 2017 Mar; 27(2):243-247. PubMed ID: 27515717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET.
    Kwee SA; Ko JP; Jiang CS; Watters MR; Coel MN
    Radiology; 2007 Aug; 244(2):557-65. PubMed ID: 17581887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.